Innovent Biologics, Inc. (IVBIY)

Market Cap	16.82B
Revenue (ttm)	1.29B
Net Income (ttm)	-12.96M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	278.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	429
Open	29.00
Previous Close	26.11
Day's Range	29.00 - 29.00
52-Week Range	19.15 - 29.00
Beta	0.23
RSI	62.80
Earnings Date	Jun 11, 2025

About Innovent Biologics

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injec...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5,659
• Stock Exchange: OTCMKTS
• Ticker Symbol: IVBIY

Financial Performance

In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.

Financial numbers in CNY